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Abstract
Background: There is a need for clinically useful biomarkers of disease activity in clinically isolated syndrome (CIS)
and relapsing remitting MS (RRMS). The aim of this study was to assess the correlation between neurofilament light
chain (NFL) in cerebrospinal fluid (CSF) and serum and the relationship between NFL and other biomarkers, subsequent
disease activity, and brain volume loss in CIS and RRMS.
Methods: A panel of neurodegenerative and neuroinflammatory markers were analyzed in repeated CSF samples from
41 patients with CIS or RRMS in a prospective longitudinal cohort study and from 22 healthy controls. NFL in serum was
analyzed using a single-molecule array (Simoa) method. “No evidence of disease activity-3” (NEDA-3) status and brain
volume (brain parenchymal fraction calculated using SyMRI®) were recorded during 4 years of follow-up.
Results: NFL levels in CSF and serum correlated significantly (all samples, n = 63, r 0.74, p < 0.001), but CSF-NFL showed
an overall stronger association profile with NEDA-3 status, new T2 lesions, and brain volume loss. CSF-NFL
was associated with both new T2 lesions and brain volume loss during follow-up, whereas CSF-CHI3L1 was
associated mainly with brain volume loss and CXCL1, CXCL10, CXCL13, CCL22, and MMP-9 were associated
mainly with new T2 lesions.
Conclusions: Serum and CSF levels of NFL correlate, but CSF-NFL predicts and reflects disease activity better
than S-NFL. CSF-NFL levels are associated with both new T2 lesions and brain volume loss. Our findings
further add to the accumulating evidence that CSF-NFL is a clinically useful biomarker in CIS and RRMS and
should be considered in the expanding NEDA concept. CSF-CXCL10 and CSF-CSF-CHI3L1 are potential markers
of disease activity and brain volume loss, respectively.
Keywords: Multiple sclerosis, Clinically isolated syndrome, Disease activity, Neurofilament light chain, CHI3L1,
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Background
Multiple sclerosis (MS) is a chronic disease characterized
by inflammation and degeneration of the central nervous
system (CNS). Relapses, new T2 lesions, and disability
progression are conventional signs of disease activity in
MS. To aid personalized treatment, prognostic biomarkers
and biomarkers of disease activity are needed. Assessing
brain volume loss and biomarkers in cerebrospinal fluid
(CSF) or serum (S) could potentially give a more compre-
hensive evaluation of disease activity [1–4].
Brain atrophy is present early in the disease course
[5, 6] and associated with disability progression [7].
Using SyMRI® to determine brain volume as brain par-
enchymal fraction (BPF) has been reported as a valid
and reproducible method with a clinically acceptable
scan time and post-processing time [8]. Neurofilament
light chain (NFL) in CSF correlates with long-term
prognosis in MS [9], is a risk factor for conversion from
clinically isolated syndrome (CIS) to relapsing remitting
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multiple sclerosis (RRMS) [10], and decreases on treat-
ment with fingolimod and natalizumab [11, 12]. We
recently reported that CSF-NFL at baseline predicted
disease activity during 2 years of follow-up in patients
with CIS and RRMS [13]. S-NFL, determined with sen-
sitive single-molecule array (Simoa) technology [14],
has been reported to be highly correlated to CSF levels
in RRMS [15].
This study aimed to assess the correlation between
S-NFL and CSF-NFL, to evaluate NFL levels in relation
to other biomarkers and disease activity parameters and
to identify parameters associated with number of new
T2 lesions and brain volume loss during 4 years of
follow-up in a longitudinal cohort of patients with newly
diagnosed CIS and RRMS.
Methods
Patients and controls
Forty-one patients with CIS or RRMS were consecu-
tively enrolled in a prospective longitudinal cohort study
of CIS and newly diagnosed MS at the Department of
Neurology, University Hospital of Linköping, Sweden.
All patients fulfilled the revised McDonald criteria from
2010 [16] for CIS or MS. Patients underwent clinical
neurological examination including expanded disability
status scale (EDSS), blood and CSF sampling as well as
MRI at baseline, and at 1, 2, and 4 years of follow-up.
Patients received immunomodulatory treatment accord-
ing to Swedish clinical practice during the study period,
from 2009 to 2016. Patient characteristics are presented
in Tables 1 and 2. For blood and CSF parameters, 22
age- and sex-matched healthy controls (HC) were
recruited from healthy blood donors. Healthy controls
were free from past and current neurological and auto-
immune disease, and their clinical neurological examina-
tions were normal as were routine findings in CSF
(Table 1). No medication, except oral contraceptives,
was allowed in healthy controls. The patients and con-
trols were included in a previous study reporting bio-
markers in relation to 2 years of follow-up, while in the
present study, we report data from 4 years of follow-up
and also include BPF and serum NFL.
Disease activity assessment
All clinical assessments regarding relapses and EDSS
were performed by the same neurologist (IH), and all
MRI examinations were thoroughly reviewed by the
same neuroradiologist. Patients that showed no relapses,
no brain MRI activity (no new or enlarging T2 lesions or
Gadolinium-enhancing lesions), and no sustained dis-
ability worsening (EDSS progression) during follow-up
were classified as showing “no evidence of disease activ-
ity”-3 (NEDA-3) (n = 20 at 1 year, n = 12 at 2 years, and
n = 7 at 4 years), while patients with relapses, brain MRI
activity, or sustained disability worsening were classified
as showing evidence of disease activity (EDA-3) (n = 21
at 1 year, n = 27 at 2 years, and n = 32 at 4 years). All 41
patients were evaluated at 1 year and 39 patients were
Table 1 Patient and healthy control characteristics at baseline
Clinical and
laboratory data
Patients
n = 41
Healthy controls
n = 22
p value
Women/men (% women) 32/9 (78%) 17/5 (77%) 0.9
Agea (years) 31 (24–36) 32 (26–41) 0.3
Diagnosis (CIS/RRMS) 19/22 N/A
Relapse within last 2 months
(yes/no)
23/18 N/A
Mean disease durationb
(months)
11.8 N/A
Median disease durationb
(months)
3.5 N/A
Disease durationb
(number of subjects)
N/A
0–1 months 10
1.25–2 months 7
2.25–3 months 3
3.25–6 months 6
6.5–12 months 7
13–24 months 3
25–36 months 2
37–48 months 1
49–120 months 2
Median EDSS 2.0 N/A
EDSS (number of subjects)
0 6 22
1.0 12
1.5 2
2.0 12
2.5 3
3.0 1
3.5 2
4.0 2
4.5 1
CSF mononuclear cell
counta
4.6 × 106/L
(1.8–9.2)
2.1 × 106/L
(0.9–2.7)
0.001
Albumin ratioa 4.8 (3.4–6.0) 4.7 (3.6–5.3) 0.5
IgG indexa 0.7 (0.5–1.1) 0.5 (0.5–0.5) < 0.001
IgG synthesis indexa 1.3 (1.0–2.1) 0.9 (0.9–1.0) < 0.001
Oligoclonal CSF IgG bands
(pos/neg)
33/8 0/22 < 0.001
p values from chi-square test for sex distribution and oligoclonal bands and
from Mann-Whitney U test for age and CSF data
N/A not applicable, DMT disease-modifying treatment
aMedian and within brackets interquartile range
bDisease duration refers to time from first symptom suggestive of
demyelinating disease
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evaluated at 2 and 4 years of follow-up. At 2 years, one
pregnant patient did not undergo MRI and one patient
had left the study. At 4 years, one additional patient had
left the study, while the previously pregnant patient
completed 4-year follow-up.
Cerebrospinal fluid and serum analyses
All CSF sampling was carried out by the same neurolo-
gist (IH), and CSF was always collected 8–12 a.m. Serum
samples were collected directly after CSF collection. One
aliquot of the CSF sample was used for cell counting,
CSF/serum albumin ratio, IgG index, IgG synthesis
index, and isoelectric focusing, all according to clinical
routines performed at the Department of Clinical Chem-
istry, Linköping University Hospital. Within 1 hour, the
remaining CSF was centrifuged (300×g for 10 min.) and
the supernatant was aliquoted and immediately frozen
and stored at − 70 °C.
CSF samples were analyzed for chemokine concentra-
tions with a multiplex bead assay (Milliplex® MAP kits,
EMD Millipore Corporation, St. Charles, MO, USA)
according to the manufacturer’s instructions, except that
an additional lower standard point was added to the
standard curve. The measurements were performed
using Luminex®200™ (Invitrogen, Merelbeke, Belgium).
For data acquisition, the software program xPONENT
3.1™ (Luminex Corporation, Austin, TX, USA) was used,
and for data analysis, MasterPlex® Reader Fit was used.
The detection limits were 16 pg/mL for CXCL1,
CXCL10, and CCL22; 3.2 pg/mL for CXCL8; and 3.9 pg/
mL for CXCL13. Values below the detection limit were
assigned half the value of the detection limit.
CSF NFL concentration was measured using the
NF-light assay according to instructions from the manu-
facturer (UmanDiagnostics, Umeå, Sweden). CSF NFH
concentration was measured using the Phosphorylated
NEFH (Human) ELISA Kit according to instructions
from the manufacturer (Abnova, Taipei City, Taiwan).
CSF MMP-9 concentration was measured using the
Human MMP-9 Base Kit according to instructions from
the manufacturer (Meso Scale Discovery, Rockville,
MD). CSF GFAP concentration was measured using an
in-house ELISA as previously described [17]. CSF
CHI3L1 and OPN concentrations were measured using
commercially available ELISAs (R&D Systems, Inc. Min-
neapolis, MN). The lower limits of quantification for the
NFH and MMP-9 assays were 31.2 and 122 pg/mL,
respectively. For the other analytes, all samples had con-
centrations within the quantifiable range of the assay.
All measurements were performed in one round of ex-
periments using one batch of reagents by board-certified
laboratory technicians who were blinded to clinical in-
formation. Intra-assay coefficients of variation were
below 15%.
S-NFL concentration was measured using the
NF-Light kit from UmanDiagnostics (UmanDiagnostics,
Umeå, Sweden), transferred onto the Simoa platform
using a homebrew kit (Quanterix Corp, Boston, MA,
USA), as previously described in detail [18]. The lower
limit of quantification (LLoQ), determined by the blank
mean signal + 10 SD, was 1.95 pg/mL. Levels in all sam-
ples were well above LLoQ. The analyses were
performed by board-certified laboratory technicians
using one batch of reagents with intra- and inter-assay
coefficients of variation below 10 and 15%, respectively.
Magnetic resonance imaging and post processing
All subjects were examined on a 1.5-T Philips Achieve
MRI scanner (Philips Healthcare, Best, The Netherlands)
using an eight-channel phased array head coil. Quantita-
tive MRI images were acquired using QMAP sequence
[19]. BPF was calculated using SyMRI® version 8.0
(SyntheticMR, Linköping, Sweden).
Statistical analyses
Statistical analyses were performed using SPSS for Win-
dows, version 23. Analyzing data sets with non-Gaussian
distribution, the Mann-Whitney U test was used to
Table 2 Patient diagnoses, relapse status, and treatment status over time
Clinical and laboratory data Baseline 1 year 2 years 4 years
Number of subjects 41 41 40 39
Diagnosis (CIS/RRMS) 19/22 12/29 9/31 7/32
Relapse within last 2 months (yes/no) 23/18 4/37 2/38 2/37
Treatment (number of subjects)
No DMT 41 17 18 18
Interferon-β 1b 0 18 12 5
Interferon-β 1a 0 1 1 1
Dimetylfumarate 0 0 0 2
Fingolimod 0 1 2 3
Natalizumab 0 4 7 10
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compare two groups and non-parametric bivariate cor-
relation analysis (Spearman) was used for correlation
analyses. The relationship between NFL in CSF and
serum was examined using bivariate linear regression
and Spearman correlation analysis, as well as Pearson
correlation analysis when sample size was > 50. Fried-
man’s test with Dunn correction for multiple compari-
sons was used to compare repeated measurements of
immunological markers in patients over time. Repeated
measures ANOVA with Bonferroni correction for mul-
tiple comparisons was used to compare repeated BPF
measurements in patients over time. Multiple linear re-
gression analysis was used to evaluate brain volume loss
over time and number of new T2 lesions over time.
Logistic regression was used when investigating NFL
and other markers in relation to NEDA. Receiver operat-
ing characteristic (ROC) curves were derived from logis-
tic regression to investigate the discriminatory power of
NFL and other markers between patients with and with-
out disease activity during follow-up. Because of mul-
tiple testing, a stringent p value of ≤ 0.01 was considered
to be significant in Mann-Whitney U tests, t tests, re-
peated measures ANOVA, and linear regression ana-
lyses. In Spearman correlation analyses, a very stringent
significance level of Spearman’s rho ≥ 0.5 and p ≤ 0.01
was used, which entailed a maximum type II error of
0.21 when n = 41 and 0.27 when n = 37. For comparisons
within the CIS group, where patient numbers were small
and comparisons few, a p value of ≤ 0.05 was considered
significant in Mann-Whitney U tests. Area under curve
(AUC) values were compared using the DeLong method,
in MEDCALC®, with the significance level set at 0.05.
All p values were based on two-tailed statistical tests.
Results
S-NFL and CSF-NFL correlate, and both are elevated in
patients at baseline
S-NFL and CSF-NFL correlated in HC (n = 22, Spear-
man’s rho 0.59, p = 0.004), in patients at baseline (n = 41,
Spearman’s rho 0.63, p < 0.001), in samples from patients
at baseline and HC combined (n = 63, Spearman’s rho
0.65, p < 0.001, and Pearson’s r 0.74 (p < 0.001). R2 from
bivariate linear regression with S-NFL as dependent
variable and CSF-NFL as independent variable (n = 63)
was 0.54, p < 0.001, equation y = 0.007x + 10.1. A correl-
ation plot is presented in Fig. 1.
To compare NFL levels in health and disease, patients
at baseline (all untreated) were compared with healthy
controls. Both S-NFL and CSF-NFL were significantly
higher in patients than in controls, see Fig. 2.
In patients, neither CSF nor serum NFL could be ex-
plained by age (R2 0.01, p = 0.5 for CSF-NFL and R2
0.003, p = 0.7 for S-NFL in simple linear regression). In
healthy controls, on the other hand, age was a significant
factor in relation to both CSF-NFL and S-NFL levels
(R2 0.73, p < 0.001 for CSF-NFL and R2 0.30, p = 0.008
for S-NFL in simple linear regression). S-NFL levels,
just like recently reported for CSF-NFL levels [13] in
this cohort, did not differ between CIS patients and
RRMS patients (p = 0.9 for S-NFL and p = 0.4 for
CSF-NFL) or between patients with and without a
relapse starting within 2 months prior to sample
collection at baseline (p = 0.7 for S-NFL and p = 0.1
for CSF-NFL). However, when including not only
baseline samples but also follow-up samples, thereby
increasing total n from 41 to 161, RRMS patients had
higher CSF-NFL (p = 0.01), but not S-NFL (p = 0.6),
than CIS patients, and NFL levels were higher in re-
lapse patients than in non-relapse patients (p = 0.004
for S-NFL and p ≤ 0.001 for CSF-NFL).
Neuroinflammatory and neurodegenerative markers at
baseline and over time
CSF and serum was collected at baseline and after 1, 2,
and 4 years. The complete descriptive data are presented
in an additional table (see Additional file 1: Table S1) for
neuroinflammatory and neurodegenerative markers (NFL,
neurofilament heavy chain (NFH), glial fibrillary acidic
protein (GFAP), chitinase 3 like 1 (CHI3L1), matrix metal-
loproteinase 9 (MMP-9), osteopontin (OPN), CXCL1,
CXCL8, CXCL10, CXCL13, and CCL22). Data on levels in
healthy controls and in patients at baseline have been
reported previously [13].
Fig. 1 Correlation between S-NFL and CSF-NFL. Correlation between
S-NFL and CSF-NFL, all samples from patients and healthy controls
(n = 63). Logarithmic scales are used on graph axes for improved
visibility (increased separation of data points), whereas statistical
analyses were performed on non-transformed linear data. Spearman’s
rho 0.65 (p < 0.001) and Pearson’s r 0.74 (p < 0.001)
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NFL levels at baseline, in particular in CSF, predict NEDA-3
status during follow-up
Area under curve (AUC) for baseline levels of NFL in
relation to disease activity during 1, 2, and 4 years of
follow-up were 0.75, 0.65, and 0.69 for S-NFL, and 0.81,
0.85, and 0.73 for CSF-NFL; ROC curves are presented
in Fig. 3. The AUC value was significantly higher at
2 years for CSF-NFL than S-NFL (p = 0.05), but did not
differ significantly at 1 and 4 years (p > 0.05). With a cut-
off value of ≥ 450 ng/L for baseline CSF-NFL, the sensi-
tivity of identifying patients with disease activity was
95% at 1 year, 93% at 2 years, and 81% at 4 years, with
specificity 50, 67, and 57%, respectively. With a cutoff
value of 14.2 ng/L for baseline S-NFL, sensitivity of identi-
fying patients with disease activity was 76% at 1 year, 74%
at 2 years, and 72% at 4 years, with specificity 50, 50, and
57%, respectively. Thus, low levels of CSF-NFL entail a
high probability of NEDA during follow-up.
Chemokines at baseline predict NEDA-3 status during
follow-up
For prediction of NEDA-3/EDA-3 during 1 and 2 years
of follow-up, baseline CXCL10 and baseline CSF-NFL
had the highest ROC-based AUCs (0.81–0.85) and for
prediction of NEDA-3/EDA-3 during 4 years of
follow-up, baseline MMP-9, CXCL10, CCL22, and
CXCL13 had the highest AUCs (0.80–0.83), see
Additional file 2: Table S2 for predictive values (AUCs)
of the whole panel of markers. There were no statisti-
cally significant differences between AUCs ≥ 0.80 (all
p ≥ 0.05). CXCL10 was the only marker with all three (1,
2, and 4 years) AUCs above 0.8.
Fig. 2 NFL in serum (a) and CSF (b) in healthy controls and patients at baseline. Lines show median and interquartile range. For S-NFL, patient
group (n = 41) median was 17 pg/mL (interquartile range 12–22 pg/mL) and healthy control (HC) (n = 22) group median was 11 pg/mL
(interquartile range 8–14 pg/mL). For CSF-NFL, patient group median was 895 pg/mL (interquartile range 300–2060 pg/mL) and HC group
median was 212 pg/mL (interquartile range 151–289 pg/mL). P- values from Mann-Whitney U test
Fig. 3 S-NFL and CSF-NFL and separation of patients with and without disease activity during follow-up. Receiver operating characteristics (ROC)
curves for baseline a S-NFL and b CSF-NFL and separation of patients with and without disease activity during follow-up after 1 (purple), 2 (blue),
and 4 (black) years. Disease activity was defined as relapses, brain MRI activity (new or enlarging T2 lesions or Gd-enhancing lesions), or disability
worsening. With a cutoff level of 450 ng/L for baseline CSF-NFL, sensitivity for identifying disease activity was 95% at 1 year, 93% at 2 years, and
81% at 4 years, with specificity 50, 67, and 57%, respectively. With a cutoff level of 14.2 ng/L for baseline S-NFL, sensitivity for identifying disease
activity was 76% at 1 year, 74% at 2 years, and 72% at 4 years, with specificity 50, 50, and 57%, respectively
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NFL levels during follow-up are associated with NEDA-3
status during follow-up
When evaluating associations with disease activity,
both in the cross-sectional and the longitudinal per-
spective, AUCs from follow-up levels as well as mean
levels of follow-up levels were assessed, in addition to
AUCs from baseline levels (table presented in
Additional file 2: Table S2). The marker with the
highest AUC for NEDA-3/EDA-3 during 1 year of
follow-up was CSF-NFL at 1 year (AUC 0.89), and for
2 years, it was mean CSF-NFL during 2 years of
follow-up (AUC 0.88). Regarding NEDA-3/EDA-3 dur-
ing 4 years of follow-up, the highest NFL AUC (mean
CSF-NFL during 4 years of follow-up, AUC 0.76) was
surpassed by others in absolute numbers (see
Additional file 2: Table S2), although not significantly
different (p ≥ 0.05). These data show that NFL levels
in CSF during follow-up, especially mean levels, are
highly associated with ongoing disease activity
expressed as NEDA-3/EDA-3.
Brain parenchymal fraction decreases over time and is
associated with increased disease activity in the early
phase
One patient was excluded at all four time points due to
very low BPF associated with congenital hydrocephalus.
Three patients were excluded due to missing data. BPF
data from the 37 patients that completed all four BPF
measurements are presented in Fig. 4. BPF mean ± SD
was 91.8 ± 2.9 at baseline, 91.3 ± 2.8 at 1 year follow-up,
90.8 ± 3.0 at 2 years follow-up, and 90.5 ± 3.2 at 4 years
follow-up. In repeated measures ANOVA with Bonferroni
correction for multiple comparisons, BPF at 1, 2, and
4 years of follow-up were significantly lower than at base-
line (p < 0.005, p < 0.001, and p < 0.001) and BPF at 2 and
4 years were significantly lower than at 1 year (p < 0.001
and 0.004). However, BPF at 4 years was not lower than at
2 years (p = 0.9). Time from baseline MRI to follow-up
MRI (mean ± SD) was 12 ± 1 months, 24 ± 1 months, and
44 ± 5 months for 1-, 2-, and 4-year follow-up,
respectively.
Mean BPF decrease was 0.49/year from baseline to
1 year, 0.50/year from baseline to 2 years, and 0.36/year
from baseline to 4 years. Mean BPF decrease from base-
line to 4-year follow-up was significantly higher in
patients with EDA-3 than in patients with NEDA-3 dur-
ing 1 year (− 1.6 vs − 0.7, p = 0.001), but not two (− 1.4
vs − 0.7, p = 0.02) and four (− 1.3 vs − 0.6, p = 0.06) years
of follow-up.
Neurofilament levels correlate with both new T2 lesions
and BPF decrease, while chemokines correlate with new
T2 lesions and CHI3L1 correlates with BPF decrease
Correlations between the panel of biomarkers (listed in
Additional file 1: Table S1) and baseline BPF, BPF de-
crease over time, baseline number of T2 lesions in brain
MRI, and number of new T2 lesions over time were ex-
amined in 37 patients with complete data sets of BPF
and the other parameters. Table 3 shows a map of the
significant correlations. Of note, neurofilament levels
correlated with both number of new T2 lesions and BPF
decrease during follow-up, whereas inflammatory che-
mokines correlated only with new T2 lesions and
CHI3L1 levels correlated only with BPF decrease.
Linear regression modeling indicates CHI3L1 as the
strongest predictor of BPF decrease
To identify the most important parameters for predic-
tion (using baseline parameters only) of, and for associ-
ation (follow-up data included as well) with, BPF
decrease and new T2 lesions, linear regression modeling
of BPF decrease and new T2 lesions during 4 years of
follow-up was performed. Details about these procedures
are given in Supplemental data. For prediction of BPF
decrease, baseline CHI3L1 was the single parameter that
performed best (R2 0.26, p = 0.001) and a peak adjusted
R2 of 0.41 (p = 0.001) was noted for a model including
age, CSF-mononuclear cells, NFH, MMP-9, CHI3L1,
and T2 lesions at baseline. As for association with BPF
decrease, adjusted R2 peaked with a model including
baseline T2 lesions, baseline OPN, and 1-year CHI3L1
(adjusted R2 0.30, p = 0.002), and the single parameter
that performed best was 1-year CHI3L1 (R2 0.29, p =
0.001). For prediction of new T2 lesions, no model
reached the significance level p ≤ 0.01, whereas for
Fig. 4 Brain parenchymal fraction in patients at baseline and during
follow-up. Brain parenchymal fraction (BPF) in patients at baseline
(BL) and at 1 year (1y), 2 years (2y), and 4 years (4y) of follow-up.
**p≤ 0.01 in repeated measures ANOVA with Bonferroni correction
for multiple comparisons. ns: not significant
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association with new T2 lesions, adjusted R2 peaked with
a model including mean CCL22, 1-year CSF-NFL, and
baseline CXCL13 (adjusted R2 0.40, p < 0.001), and the
single parameter that performed best was 1-year
CSF-NFL (R2 0.32, p < 0.001). Details of linear regression
statistics are given in Additional file 3.
CIS converters
Within the CIS group at baseline (n = 19), CXCL10, NFL,
and MMP-9 in CSF were significantly higher (p ≤ 0.05 in
Mann-Whitney U tests) in patients that converted to
RRMS during 4 years of follow-up (n = 12) than in
non-converters (n = 7), whereas S-NFL (p = 0.10) and the
other markers (p = 0.07–0.90) did not differ. For the 12
CIS patients that converted to RRMS during the study,
multiple regression modeling of time to conversion
resulted in a highly significant model (adjusted R2
0.81, p = 0.006) when including baseline CSF levels of
CXCL1, CXCL10, CXCL13, and NFL, and number of
T2 lesions at baseline).
Discussion
In the present study, we report a correlation between
NFL levels in CSF and serum (Pearson’s r 0.74) that is in
line with what has been reported by others [15, 20]. Al-
though baseline S-NFL was correlated with subsequent
Table 3 Correlations between neuroinflammatory and neurodegenerative markers, baseline number of T2 lesions, number of new
T2 lesions, and BPF change during follow-up
T2,
BL
New T2,
1 year
New T2,
2 years
New T2,
4 years
BPF change,
4 years
S-NFL, BL 0.33 0.55* 0.43 0.44 − 0.24
S-NFL, 1y 0.45 0.43 0.33 0.34 − 0.56*
S-NFL, 2y mean 0.45 0.52* 0.37 0.37 − 0.37
S-NFL, 4y mean 0.41 0.43 0.32 0.35 −0.42
CSF-NFL, BL 0.29 0.60* 0.64* 0.51* − 0.20
CSF-NFL, 1y 0.59* 0.59* 0.58* 0.50* − 0.54*
CSF-NFL, 2y mean 0.43 0.62* 0.65 0.54 −0.33
CSF-NFL, 4y mean 0.41 0.55* 0.60* 0.53* − 0.35
MMP-9, BL 0.46 0.53* 0.47 0.42 − 0.16
MMP-9, mean 0.38 0.51* 0.51* 0.46 −0.26
CHI3L1, BL 0.49 0.42 0.36 0.26 −0.55*
CHI3L1, 1y 0.45 0.35 0.30 0.30 − 0.60*
CHI3L1, 2y 0.31 0.13 0.11 0.13 − 0.50*
CHI3L1, mean 0.42 0.30 0.24 0.20 − 0.54*
OPN, BL 0.51* 0.34 0.21 0.23 − 0.52*
CXCL1, BL 0.51* 0.56* 0.42 0.23 − 0.34
CXCL10, BL 0.50* 0.58* 0.48 0.41 − 0.26
CXCL10, mean 0.47 0.51* 0.42 0.34 − 0.37
CXCL13, BL 0.37 0.51* 0.52* 0.46 − 0.26
CXCL13, mean 0.40 0.49 0.52* 0.45 − 0.33
CCL22, mean 0.29 0.49 0.57* 0.54* − 0.31
T2, BL 1.00 0.48 0.39 0.27 − 0.56*
New T2, 1y 0.48 1.00 0.86* 0.66* − 0.44
New T2, 2y 0.39 0.86* 1.00 0.83* − 0.47
New T2, 4y 0.27 0.66* 0.83* 1.00 − 0.36
BPF decrease, 4y − 0.56* − 0.44 − 0.47 − 0.36 1.00
Magnitude of correlation coefficients (Spearman’s rho) from bivariate non-parametric correlation analyses (Spearman) are shown
2y mean refers to the mean of levels at baseline, 1-year, and 2-year follow-up
4y mean refers to the mean of levels at baseline, 1-year, 2-year, and 4-year follow-up
T2, BL: number of T2 lesions in baseline brain MRI
New T2, 1y, 2y and 4y: number of new T2 lesions in brain MRI during 1, 2, and 4 years of follow-up, respectively, compared to baseline MRI
BPF change, 4y: brain parenchymal fraction decrease during 4 years of follow-up
S serum, CSF cerebrospinal fluid, BL baseline
*Spearman’s rho ≥ 0.50 and p ≤ 0.001
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disease activity, CSF NFL seems to reflect disease activity
better since baseline CSF-NFL predicted NEDA-3 during
2 years of follow-up significantly better than S-NFL, and
moreover, CSF-NFL levels showed an overall stronger
correlation profile than serum levels with regard to
number of new T2 lesions. Our findings confirm
CSF-NFL as a prognostic biomarker for conversion
from CIS to MS [13, 21], association with disease ac-
tivity [9, 13], and change in brain volume [22]. The
fact that all these findings were significant in our
moderately sized cohort, and the finding that
CSF-NFL performed well compared with other
markers and showed associations with both disease
activity and brain volume loss, render further support
for CSF-NFL as a clinically useful biomarker in MS.
Interestingly, 1-year CSF-NFL levels correlated signifi-
cantly with both new T2 lesions and BPF decrease dur-
ing 4 years of follow-up. For other markers, they were
either associated with BPF decrease (CHI3L1 and OPN)
or with new T2 lesions (CXCL1, CXCL10, CXCL13,
CCL22, and MMP-9). In linear regression modeling of
new T2 lesions, the combination of 1-year CSF-NFL,
CCL22 (mean level) and CXCL13 (baseline level) per-
formed better than 1-year CSF-NFL alone, suggesting an
added value of combining several markers, which was
recently shown for chemokines and OPN [23]. Of note,
chemokines, in contrast to most cytokines, are present
at measurable levels in CSF. We here showed that
CXCL10 was able to predict disease activity at all
follow-up time points (NEDA-3 status at 1, 2, and
4 years) and that CXCL10 was also higher in
CIS-converters than in non-converters, findings that
suggest CXCL10 as a biomarker in CIS and RRMS. This
has been indicated in other studies as well [24, 25]. As
for brain volume loss, CHI3L1 had the highest predictive
value, and further studies may confirm its clinical role.
Expanding NEDA-3 to NEDA-4 and NEDA-5 by in-
cluding brain volume loss and biomarkers could improve
assessment of disease activity in MS. Number of T2
lesions and T2 lesion volume in conventional MRI cor-
relate poorly to clinical disease manifestations and dis-
ease progression in MS [26], although lesion volume has
been reported to predict long-term disability [27]. Meas-
uring brain volume loss as BPF decrease is non-invasive
and logistically easy, only marginally extending time in
the MRI-scanner. However, the use of BPF measure-
ments and other brain volume quantification methods
are hampered by technical limitations, physiological vari-
ation, and difficulties in identifying optimal cutoff levels
for annual brain volume loss [3, 28]. It has been argued
that although suitable for cohort studies, BPF measure-
ments do not seem adequate for assessing changes in in-
dividual patients over months or a few years [28].
CSF-NFL, on the other hand, is a biomarker that
provides clinically useful information and therefore
emerges as a strong candidate for inclusion in the NEDA
concept, although cutoff levels need to be settled. As for
the more feasible S-NFL, a reasonable correlation with
CSF-NFL and an ability to reflect disease activity in MS
[15, 29, 30] was here confirmed, reiterating the sugges-
tion of S-NFL as a promising biomarker. Indeed,
recently published data from a large MS cohort show
that higher S-NFL is clearly associated with worse clin-
ical (EDSS progression) as well as MRI (T2 lesions and
atrophy) outcome [31]. CSF-NFL was however not re-
ported, and in our cohort, S-NFL did not perform as
well as in that study [31]. It could be that smaller sample
size affected our results, but still we noted that
CSF-NFL yielded strong results in our single-center
cohort. The exciting development of reliable high sensi-
tivity assays has enabled detection of brain-derived
markers in serum and plasma, but still these levels con-
stitute a proxy for the levels in CSF. As long as there is
no absolute correlation between CSF- and S-NFL, it
seems clear that CSF levels should better reflect CNS
pathology than blood, as supported by the stronger asso-
ciations that we see between CSF-NFL and NEDA-3 as
well as T2 lesions and brain volume, compared with
S-NFL. Also, some markers of inflammation, such as the
chemokines CXCL10 and CXCL13, have been reported
to be elevated and to correlate with disease activity when
measured in the CSF, but not in plasma [13, 32, 33].
Since CSF analysis is recommended in the diagnostic
process [34], it is uncontroversial and appropriate to
include NFL and other biomarkers in CSF at this stage.
Also in monitoring of disease activity and treatment
effects, the best possible medical information would be
obtained by CSF analyses, which in the future also may
include tools to personalized treatment [23, 35]. On the
other hand, aspects like patient discomfort and various
practical issues limit the use of CSF biomarkers, whereas
blood samples can usually be easily obtained. We be-
lieve that both CSF- and S-NFL should be part of the
initial diagnostic work-up for all patients and that
follow-up CSF analyses should be considered when as
complete as possible information is required to make
a clinical decision. For many patients follow-up CSF
analyses may not be motivated, whereas S-NFL could
be liberally considered as an addition to NEDA-3
evaluation. As for the other neuroinflammatory and
neurodegenerative markers in our panel, we have pre-
viously reported that chemokine levels in plasma did
not differ significantly between patients and healthy
controls [13]. There have been reports by others that
e.g. CHI3L1 in serum may be a useful biomarker [36,
37], but so far, S-NFL shows most promise [31].
Limitations of this study include the cohort size, vary-
ing treatment and lack of MRI data from healthy
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controls. Varying treatment regimens in the cohort
could lower the prognostic value of baseline biomarker
levels. However, despite the fact that some patients re-
ceived disease modifying drugs during follow-up, baseline
levels of some proteins clearly showed prognostic value.
We also focused on NEDA status, new T2 lesions, and
BPF decrease in relation to follow-up levels and mean
levels of NFL, etc., thereby exploring association over time
instead of prediction. When examining, for example, the
association between mean level of NFL during follow-up
and NEDA-3 status during follow-up, the impact of treat-
ment is negligible or small unless treatment affect NFL
and NEDA-3 status very unevenly. Study strengths are the
control group, consisting of sex- and age-matched healthy
individuals, that the patient group consisted of
well-characterized CIS and MS patients examined and
thoroughly followed up prospectively by the same neur-
ologist in a standardized way and that all patients were
untreated at baseline. Also, a broad panel of potential
biomarkers was included. The present study provides
4-year follow-up data on CSF-NFL in a patient cohort
that we have previously presented 2-year follow-up
data from, and in addition, we report S-NFL data as
well as brain volume analyses for the entire study
period (4 years). Taken together, this is the first study
that reports longitudinal data on these markers,
including NFL levels in CSF and serum, in relation to
both NEDA-3 and brain volume loss in a clinical
setting study.
Conclusions
We show that although serum and CSF levels of NFL
correlate significantly, CSF-NFL predicts and reflects
disease activity better than S-NFL during follow-up in
our cohort of patients with CIS and RRMS. CSF-NFL is
associated with both new T2 lesions and brain volume
loss during follow-up. Our findings further add to the
accumulating evidence that CSF-NFL is a useful bio-
marker in CIS and RRMS and should be considered in
the expanding NEDA concept. Our findings also support
S-NFL as a potential biomarker in CIS and RRMS.
Other biomarkers that need further attention include
CXCL10 and CHI3L1 for prediction of NEDA-3 and
brain volume loss, respectively.
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